REG - AstraZeneca PLC - Block listing Interim Review

AstraZenecaAnnouncement

02/12/2019 15:05

RNS Number : 3770V
AstraZeneca PLC
02 December 2019
 


02 December 2019 15:00 GMT
 
 
Block Listing Six Monthly Return
 
Information provided on this form must be typed or printed electronically and provided to an ris.
 
Date: 2 December 2019
 



Name of applicant:


ASTRAZENECA PLC




Name of scheme:


ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE OPTION PLAN; ASTRAZENECA ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED SHARE OPTION SCHEME




Period of return:


From:


1 June 2019


To:


30 November 2019




Balance of unallotted securities under scheme(s) from previous return:


1,248,036




Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):


0




Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):


136,370




Equals: Balance under scheme(s) not yet issued/allotted at end of period:


1,111,666










 



Name of contact:


CAMILLA JOHNSTONE




Telephone number of contact:


020 3749 5000



 
 
 
 
About AstraZeneca
AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.
 



Media Relations












Gonzalo Viña






+44 203 749 5916




Rob Skelding


Oncology


+44 203 749 5821




Rebecca Einhorn


Oncology


+1 301 518 4122




Matt Kent


BioPharmaceuticals


+44 203 749 5906




Jennifer Hursit


Other


+44 203 749 5762




Christina Malmberg Hägerstrand


Sweden


+46 8 552 53 106




Michele Meixell


US


+1 302 885 2677


















Investor Relations












Thomas Kudsk Larsen






+44 203 749 5712




Henry Wheeler


Oncology


+44 203 749 5797




Christer Gruvris


BioPharmaceuticals (Cardiovascular, Metabolism)


+44 203 749 5711




Nick Stone


BioPharmaceuticals (Renal) Environmental, Social and Governance


+44 203 749 5716




Josie Afolabi


BioPharmaceuticals (Respiratory)
Other medicines


+44 203 749 5631




Craig Marks


Finance
Fixed income


+44 7881 615 764




Jennifer Kretzmann


Corporate access
Retail investors


+44 203 749 5824




US toll-free






+1 866 381 72 77



 
 
Adrian Kemp

Company Secretary
AstraZeneca PLC
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BLRFSEFLEFUSEDE